Therapy-related myeloid neoplasm
MONDO:0006450Acute myeloid leukemias, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms arising as a result of the mutagenic effect of chemotherapy agents and/or radiation that are used for the treatment of neoplastic or non-neoplastic disorders.
Also known as: acute myeloid Leukaemias and myelodysplastic syndromes, therapy-related, therapy-related AML and MDS, therapy-related acute myeloid leukaemia and myelodysplastic syndrome, therapy-related acute myeloid leukemia and myelodysplastic syndrome, therapy-related myeloid neoplasm, TMN, therapy-related myeloid neoplasms
3110 clinical trials for this condition and its sub-types, 54 tagged with Therapy-related myeloid neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Three-Drug cocktail aims to tame transplant complications in blood cancer patients
Disease control Not yet recruitingThis trial investigates whether adding bortezomib and sitagliptin to standard post-transplant cyclophosphamide can prevent graft-versus-host disease (GvHD) in adults with blood cancers receiving a stem cell transplant. Participants receive the drug combination after transplant, w…
Phase 1/2 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill aims to keep leukemia away after transplant
Disease control Not yet recruitingThis study tests a new oral drug called revumenib in people with acute myeloid leukemia (AML) who have certain genetic changes. After a stem cell transplant, participants will take revumenib or a placebo to see if it helps keep the cancer from coming back. The trial involves 144 …
Phase 2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New trial aims to wipe out hidden leukemia before transplant
Disease control Not yet recruitingThis Phase 2 trial tests whether adding other drugs to standard chemotherapy can eliminate leftover leukemia cells in adults aged 18-59 before a stem cell transplant. Participants who still have detectable disease after initial treatment will receive one of four drug combinations…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New study tests if SPECT imaging can forecast prostate cancer treatment success
Knowledge-focused Not yet recruitingThis study will look at whether SPECT scans taken after Lu-PSMA therapy can help predict how well patients with metastatic castration-resistant prostate cancer (mCRPC) are doing. Researchers will measure tumor activity and volume on the scans and compare them to standard PET-base…
Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC